| Bioactivity | Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD)[1]. |
| Invitro | Zevaquenabant can simultaneously inhibit CB1 receptors and inducible NOS in peripheral organs[1]. |
| In Vivo | Zevaquenabant (3 mg/kg; p.o.; for 28 days) improves renal morphological and functional parameters in diet-induced obese mice[1]. Animal Model: |
| Name | Zevaquenabant |
| CAS | 1998760-00-1 |
| Formula | C25H21ClF3N5O2S |
| Molar Mass | 547.98 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Udi S, et al. Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease [published correction appears in Br J Pharmacol. 2021 Mar;178(5):1250]. Br J Pharmacol. 2020;177(1):110-127. |
Zevaquenabant
CAS: 1998760-00-1 F: C25H21ClF3N5O2S W: 547.98
Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducib
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.